diation therapy, carbon beam radiation therapy, and radiosurgery. 3, 9, 10, 14, 25, 28, 32 Both the absence of prospective comparative studies and the limited knowledge of the prognostic profile of these tumors explain that optimal treatment of skull base chordomas remains challenging. A recently published study has associated cadherin expression with the clinical prognosis of the disease. 29 This current multicenter study was conducted to analyze the pattern of care, clinical course, and prognostic factors of patients with clival chordomas.
Methods

Patient Population
Patients with either de novo or recurrent skull base chordomas (WHO Grade I) 16 who were consecutively treated (between 1996 and 2008) in one of the 5 studyassociated German university hospitals (Bonn, Erlangen, Frankfurt, Munich, and Tübingen) were included. No patient had received any form of radiation therapy at the time of study inclusion. Radiation therapy was normally not performed after complete resection. In case of residual tumor after surgery, PBRT was the preferred treatment modality. Follow-up evaluation was done 3 months after surgery and then in 6-month intervals in all centers. The following parameters were analyzed: sex, age, Karnofsky Performance Scale (KPS) score, neurological deficits, duration of preoperative symptoms, de novo versus recurrent tumor status at study inclusion, tumor extension, surgical approach, extent of resection, type and dose of adjuvant therapy, and expression of cadherins.
Magnetic Resonance Imaging
Neuroradiological assessment was retrospectively performed in a blinded fashion at each of the academic centers. Standard MRI included axial T2-weighted sequence with a slice thickness of 2-3 mm, and T1-weighted sequences (with and without contrast enhancement) with a slice thickness of 1-2 mm. Tumor size was assessed by a 3D volume calculation using the largest diameter in the axial, coronal, and sagittal planes. Additionally, involvement of petrosal bone, condyles, or clivus; infiltration of dura; and compression of brainstem was noted. In selected cases CT was available to assess involvement of bone structures. Neuroradiological assessments at study inclusion and at first clinical follow-up 3 months after surgery were available for all patients and were used for comparative analysis. Complete resection was considered to have been achieved if no residual tumor was seen. Tumor removal of more than 50% was classified as a partial resection. Tumor removal below this threshold was categorized as extended biopsy. Tumor progression was determined by follow-up MRI and was suspected if a new lesion was seen.
Histopathology and Semiquantitative Analysis of Cadherin Expression
Central review of histopathology according to the classification of tumors of soft tissue and bone 16 was done at the Center for Neuropathology and Prion Research, Ludwig Maximilian University of Munich, and confirmed the diagnosis of chordoma Grade I in all patients. Semiquantitative analysis of N-cadherin and E-cadherin expression was also centrally done at this center. Tumor samples were fixed with 4% buffered formalin (Fisher Scientific GmbH), paraffin embedded, and subjected to routine staining on a benchmark staining machine with a standard 3,3ʹ-diaminobenzidine (DAB) detection system according to the manufacturer's instructions (Ventana Medical Systems). Tumor morphology in 2-mm paraffin sections was visualized using H & E staining as well as mouse monoclonal anti-human cytokeratin antibody (clone LU-5, Dianova). Expression of cadherins was analyzed using anti-N-cadherin mouse monoclonal antibody (clone 13A9, Calbiochem) and mouse monoclonal antihuman E-cadherin antibody (clone 36B5, Novocastra), respectively. Semiquantitative analysis of protein expression was performed in an independent and blinded fashion by 2 experienced neuropathologists (S.E. and H.K.) and was classified according to a 3-scaled staining score as follows: 29 immunostaining < 10%, 10%-50%, and > 50% of the respective total chordoma tissue under investigation refer to a staining score of 1 (weak), 2 (moderate), and 3 (strong), respectively. In case of discordant findings, a conference for reevaluation was initiated to achieve a consensus concerning the expression score.
Statistical Analysis
The reference point of the study was the date of first surgery. Last follow-up was performed in June 2012. Primary and secondary end points were tumor progression and death. Progression-free survival and OS were analyzed using the Kaplan-Meier method. Prognostic factors were obtained from the proportional hazards model. Parameters tested in univariate models are presented in Table 1 . Only those being significant were subsequently included in multivariate proportional hazards models. For comparison of continuously scaled patient-and tumor-related parameters, the Wilcoxon test was used. Categorical variables were analyzed using the chi-square test or the Fisher's exact test, if necessary. Statistical significance was assigned to p < 
Results
Patient Characteristics
The study cohort comprised 47 patients (26 men and 21 women). Basic characteristics of the study population are presented in Table 2 . Men and women did not differ in any of the addressed patient-and tumor-related parameters (Table 2 ). Ten patients (21%) had undergone prior resection at another institution, and 37 patients (78.7%) suffered from de novo tumors. The groups did not differ in any of the patient-or tumor-related parameters. Magnetic resonance imaging revealed brainstem compression in 20 patients (42.6%), the condyles were involved in 8 patients (17%), petrosal bone was affected in 17 patients (36.2%), and dural infiltration was seen in 8 patients (17%) (a typical example of a clival chordoma is given in Fig. 1 ).
Pattern of Care and Clinical Course
The preferred operative approaches are summarized in Table 3 . Complete resection and partial resections were achieved in 7 patients (14.9%) and 38 patients (80.9%), respectively. Two patients (4.3%) underwent extended biopsy only. All patients with complete resection were men (7 of 26 vs 0 of 21 women, p = 0.036). Surgical morbidity was documented for 8 patients (17.0%) and included 6 patients with postoperative worsening of preexisting cranial nerve dysfunction as well as 2 patients with new deficits. Perioperative complications were not associated with any of the patient-, tumor-, or surgery-related covariates.
Thirty patients (63.8%), mainly those with residual tumors after initial surgery (28 of 40 with residual tumors vs 2 of 7 without residual tumors, p = 0.035), received adjuvant treatment; PBRT was applied in 22 patients (mean maximal dose 59.3 Gy, range 40-66 Gy), conventionally fractionated radiotherapy in 3 patients (mean maximal dose 65 Gy, range 60-70 Gy), and radiosurgery in 5 patients (mean maximal dose 24 Gy, range 17-36 Gy). The applied adjuvant treatment regimens were similar for men and women and did not differ between patients with de novo or recurrent tumor status at the time of study inclusion.
During a median follow-up of 5.2 years (range 0.4-15.8 years) 26 patients (55.3%, 14 of 26 men and 12 of 21 women) suffered from local tumor progression and 8 patients died of progressive disease (7 men and 1 woman). Distant recurrences outside the initial treatment volume were not observed. Adjuvant radiation therapy was not associated with prolonged PFS (p = 0.25). The median PFS was shorter in men than in women (4.8 vs 9.8 years, respectively; p = 0.04) (Fig. 2 ). All patients with recurrent disease underwent a second surgery followed by proton beam radiation therapy in 4 patients and radiosurgery in 2 patients. Overall, 38 patients (80.9%) underwent some type of radiation therapy.
Complete resection correlated with more favorable OS (p = 0.04) and radiation therapy did not (p = 0.3). Estimated median OS was worse for male patients even though total resection was achieved more frequently (8.3 years vs not reached, p = 0.03). The estimated 5-year survival rates were 83.3% for all patients, 72.0% for men, and 100% for women.
N-Cadherin and E-Cadherin Expression and Outcome
Typical staining patterns are shown in Fig. 3 . Semiquantitative analysis revealed Grade I expression of N-cadherin in 1 patient (2%), Grade II expression in 4 patients (9%), and Grade III expression in 41 patients (89%). Immunohistochemistry could not be evaluated in 1 patient. For E-cadherin, semiquantitative analysis revealed Grade I expression in 26 patients (57%), Grade II expression in 8 patients (17%), and Grade III expression in 12 patients (26%). N-cadherin expression was inversely correlated with low E-cadherin expression (p < 0.0001). These findings did not differ between male and female patients and those with de novo and recurrent tumor status (for more details see Table  2 ). No significant correlation between N-and E-cadherin expression and outcome was found (Fig. 4) .
Prognostic Factors
Results of univariate analysis are shown in Table 1 . Male sex was a prognostic factor for shortened PFS (p = 0.04) and OS (p = 0.03) (Table 1; Fig. 2 ). Complete resection correlated with prolonged OS (p = 0.04); no association with PFS was seen (p = 0.72). In multivariate analysis only male sex retained prognostic relevance (p = 0.03) for both PFS and OS. The influence of surgery was lost. Age, duration of symptoms, initial KPS score, brainstem compression, involvement of the petrous bone, infiltration of the dura mater, N-and E-cadherin expression, and modality and dose of radiation therapy did not influence clinical outcome.
Discussion
Skull base chordomas are heterogeneous lesions with respect to their anatomical location, growth behavior, pattern of recurrence, and response to treatment. 19, 20, 25 Optimal management remains a matter of debate.
11,25 Current concepts frequently include radical surgery and adjuvant treatment of residual tumors, preferably in the form of PBRT. Given the fact that outcome considerably varies after treatment, prognostic factors are urgently needed to facilitate personalized treatment strategies. In the current study we demonstrate that male sex is associated with significantly shorter PFS and OS. These differences were not confounded by other covariates such as tumor size, duration of symptoms, involvement of critical anatomical structures, and adjuvant treatment regimens. Noteworthy, complete resection was exclusively achieved in the male subpopulation of this series. Sex disparities in the prognosis in favor of the female subpopulation have been reported for other tumor entities such as bladder cancer, non-small cell lung cancer, breast cancer, and soft-tissue sarcoma. 13, 17, 21, 23 The underlying mechanisms of sex-dependent differences in outcome have not been elucidated yet.
In accordance with other reports, complete resection correlated with better OS in 1-variable prognostic models. 11, 12 The influence of extent of resection, however, was lost after multivariate analysis. It cannot be excluded that the relatively low frequency of complete resections (15%) might have weakened the prognostic impact of this covariate in multivariate models. Other studies have reported complete resection rates of 0%-66%. 1, 4, 8, 11, 12, 19, 26 However, comparison of surgical results of different study populations is hampered by resection criteria that are not strictly applied, which often only refer to the surgeon's intraoperative impression, differences in tumor location, and sometimes by additional inclusion of spinal chordomas. In the current series of patients with skull base chordomas who were considered eligible for surgery, tumor extension exhibited an intimate relationship to the brainstem in 21% of the study population and involved the craniocervical junction in an additional 17%. Complex tumor location/extension might have contributed to the relatively low frequency of complete resections in the current report. Prospective multicenter trials are necessary to more properly assess the impact of surgery in skull base chordomas.
Reported complication rates after surgery were at the lower end of those reported in the literature, which ranged from as low as 16% to as high as 60%. 8, 11, 12, 26 Worsening or development of new cranial nerve dysfunction was seen in 17% of patients; no functional instability of the craniocervical junction occurred after surgery. Notably, perioperative complications could not be allocated to any of the applied surgical approaches and were found at similar frequencies in patients with de novo and recurrent tumors.
Overall, despite the fact that complete resection was only achieved in a relatively small number of patients in Recently, a preliminary study announced N-and Ecadherin expression as a prognostic marker in clival chordomas. 29 Cadherins are transmembranous proteins that form a complex with cytoplasmic catenins, which is critical for stabilization of the cytoskeleton. They are critically involved in several dynamic processes during embryonic development (N-cadherin) as well as Ca 2+ -dependent differentiation and stabilization of mature epithelial tissues (E-cadherin). Triana et al. found significantly shorter PFS and survival times for tumors showing a combination of both upregulated N-cadherin expression and downregulated E-cadherin expression. 29 Even though we also found an inverse correlation between N-and E-cadherin expression, we were unable to identify any prognostic impact of these proteins. Expression patterns were not influenced by sex and did not differ in de novo and recurrent tumors. It has been speculated that an increased ratio of Ncadherin/E-cadherin expression indicates a shift from an epithelial toward a more aggressive mesenchymal phenotype correlating with impaired clinical outcome scores. This hypothesis of Triana and colleagues, however, was not supported by our data. 29 Our study was not designed to analyze the efficacy of radiation therapy. The vast majority of patients with residual tumors underwent radiation therapy; in contrast, radiation therapy was withheld in 6 of 8 patients who underwent a complete resection. Given the fact that complete resection was exclusively performed in the male subpopulation and that males did worse in the current series, it remains a matter of debate whether adjuvant ra- diation therapy should be stringently applied in patients with skull base chordomas independent of the extent of resection.
In accordance with the literature, PBRT was the preferred modality in this series (22 of 30 patients) as it has been suggested to provide longer survival rates at lower risk for the patients than conventional megavoltage radiotherapy. However, the current literature does not provide enough evidence yet to support superiority of protons over photons in skull base chordomas. The role of Gamma Knife or linear accelerator (LINAC) radiosurgery is also poorly defined. 9, 11, 22 We are aware that extended time intervals and collections from multiple centers are necessary to include a high number of patients with skull base chordomas for evaluation of prognosis and outcome. 11 Given the fact that treatment protocols are continuously modified or improved, the exact elucidation of treatment effects is notoriously difficult.
Conclusions
Sex appears to be an independent prognostic factor for PFS and OS in skull base chordomas. Complete resection might be associated with favorable OS. N-cadherin or E-cadherin expression did not gain prognostic relevance. The male subpopulation might require more aggressive initial treatment even in cases of complete tumor resection. Further prospective studies are needed to elucidate the potential mechanism of sex disparity with regard to tumor progression and prognosis.
